Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
1(7%)
Results Posted
20%(2 trials)
Terminated
2(13%)

Phase Distribution

Ph not_applicable
4
27%
Ph phase_1
4
27%
Ph phase_2
7
47%

Phase Distribution

4

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
4(26.7%)
Phase 2Efficacy & side effects
7(46.7%)
N/ANon-phased studies
4(26.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

71.4%

10 of 14 finished

Non-Completion Rate

28.6%

4 ended early

Currently Active

1

trials recruiting

Total Trials

15

all time

Status Distribution
Active(1)
Completed(10)
Terminated(4)

Detailed Status

Completed10
Terminated2
Withdrawn2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
1
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (26.7%)
Phase 27 (46.7%)
N/A4 (26.7%)

Trials by Status

active_not_recruiting17%
completed1067%
terminated213%
withdrawn213%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT04975698Phase 2

HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

Completed
NCT05170828Phase 1

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Withdrawn
NCT05900401Phase 1

Delayed Tolerance Through Mixed Chimerism

Active Not Recruiting
NCT03240731Phase 2

HLA Haploidentical Bone Marrow Transplant in Patients With Severe Sickle Cell Disease

Completed
NCT00574626Not Applicable

Comparing Autologous Peripheral Blood Stem Cell to Bone Marrow Transplantation for Recurrent Non-Hodgkin's Lymphoma

Completed
NCT02224872Phase 2

Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia

Completed
NCT04282174Phase 2

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Withdrawn
NCT00000647Not Applicable

An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection

Completed
NCT02638467Phase 2

Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy

Completed
NCT01342289Phase 1

Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

Completed
NCT02029638Phase 2

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

Terminated
NCT01383434Phase 2

Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia

Terminated
NCT00023530Not Applicable

Blood and Marrow Transplant Clinical Research Network

Completed
NCT00187018Not Applicable

Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study

Completed
NCT00144729Phase 1

Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor

Completed

All 15 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
15